Advertisement

Topics

Latest "Bavarian Nordic Announces Initiation Phase Booster Study Universal" News Stories

05:41 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Bavarian Nordic Announces Initiation Phase Booster Study Universal" found in our extensive news archives from over 250 global news sources.

More Information about Bavarian Nordic Announces Initiation Phase Booster Study Universal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Bavarian Nordic Announces Initiation Phase Booster Study Universal for you to read. Along with our medical data and news we also list Bavarian Nordic Announces Initiation Phase Booster Study Universal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Bavarian Nordic Announces Initiation Phase Booster Study Universal Companies for you to search.

Showing "Bavarian Nordic Announces Initiation Phase Booster Study Universal" News Articles 1–25 of 31,000+

Saturday 16th February 2019

Medical News Today: Diabetes and Alzheimer's: What's the link?

Although scientists have linked Alzheimer's and diabetes, the exact connection has been difficult to unpick. A recent study now gives further insight.


Interim data from the Merck KGaA, Darmstadt, Germany and Pfizer Alliance’s PhIII study in advanced RCC published in @NEJM. Additional data in advanced RCC presented at #GU19 Learn more here: https://www.pfizer.com/news/press-release/press-release-deta

Interim data from the Merck KGaA, Darmstadt, Germany and Pfizer Alliance’s PhIII study in advanced RCC published in @NEJM. Additional data in advanced RCC presented at #GU19 Learn more here: https://www.pfizer.com/news/press-rel

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Satu...


KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent Data Consistent Across all IMDC Risk Groups and Regardless of PD-L1 Expression Merck (NYSE: MRK), known as MSD ou...

. @GileadSciences’ Lead Liver Disease Candidate Selonsertib Fails Phase III Trial in NASH: http://ow.ly/WWoS30nFK5S pic.twitter.com/g3nPSuGjll

. @GileadSciences’ Lead Liver Disease Candidate Selonsertib Fails Phase III Trial in NASH: http://ow.ly/WWoS30nFK5S  pic.twitter.com/g3nPSuGjll

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-ASCO-Genitourinary-Cancer-Symposium.html …

$AVEO Announces Oral Presentation of TIVO-3 Trial Topline Results at the ASCO #GU19 https://www.businesswire.com/news/home/20190216005008/en/AVEO-Oncology-Announces-Oral-Presentation-TIVO-3-Trial …

$AVEO Announces Oral Presentation of TIVO-3 Trial Topline Results at the ASCO #GU19 https://www.businesswire.com/news/home/20190216005008/en/AVEO-Oncology-Announces-Oral-Presentation-TIVO-3-Trial …

AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Di...

Low physical fitness and obesity during teen years linked to disability later in life

1. This prospective cohort study found that both low physical fitness and obesity during adolescence is associated with increased risk for disability later in life. 2. Obesity during adolescence, measured through body mass index (BMI), was found to be the greatest predictor of all-cause disability later in life for Swedish men. Evidence Rating Level: 1 […] Source: 2 Minute Medicine

Ablynx takes Phase III hurdle in acquired TTP

Roche mets endpoints in first-line NSCLC study

COR Medspa Now Open, the Leading Aesthetic and Wellness Provider in Denville, NJ

DENVILLE, N.J. (PRWEB) February 15, 2019 State-of-the-art aesthetic and wellness provider, COR Medspa, announces its opening in Denville, NJ. Created by recognized physicians in urology, COR Medspa is committed to helping patients realize their best with the most effective aesthetic and sexua...

Smoking and HLA Genes in Rheumatoid Arthritis

(MedPage Today) -- New study sorts out relative contributions of these risk factors

News digest – HPV stigma, ultra-processed foods, ‘simple’ cancer blood test and why measles isn’t a cancer cure

Science blog Stigma around HPV infection causes concern Misunderstanding and perceived stigma around the human papillomavirus (HPV) infection is concerningly high and could put women off cervical screening, reports the Independent and others. The results

Do Nutraceuticals Help Bipolar Depression?

Not according to this randomized, controlled study, which showed no benefit with N-acetylcysteine alone or combined with a mix of other mitochondrial-targeted supplements

Friday 15th February 2019

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer

Dr Nicholas van As speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about analysis of acute toxicity from the randomised phase III PACE-B trial comparing tereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately...

Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code

Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets. On February 11, 2019, Aradigm determined that without confirmation of funding from their primary investor and partner, the Company would not...

[Corrections] Correction to Lancet Infect Dis 2017; 17: 330–38

Kraemer MUG, Faria NR, Reiner RC Jr, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. Lancet Infect Dis 2017; 17: 330–38—The appendix of this Article has been updated. This correction has been made to the online version as of Feb 15, 2019.

Medical News Today: Exercise boosts well-being by improving gut health

Researchers believe that physical activity can influence a person's overall health because of its effect on gut health. A new study explains the link.

Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that updated data from a Phase 1 study of the glutaminase inhibitor telaglenas...

Drug combination may become new standard treatment for advanced kidney cancer

(Dana-Farber Cancer Institute) A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

Avapritinib receives Phase III clinical trial approval for GIST in China

SUZHOU, China, Feb. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors (GIST). The study will be part of the global VOYAGER Phase II...

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

Data that further supports clinical adoption of SelectMDx and ConfirmMDx presented at the Annual ASCO Genitourinary Cancers Symposium IRVINE, Calif. and HERSTAL, Belgium (PRWEB) February 15, 2019 MDxHealth SA (Euronext: MDXH.BR) today announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for Prostate Cancer d...

Pumped Milk Gives Infants Different Bacteria Than Breastfeeding, Study Says

Mother’s milk provides sustenance for babies. Now researchers find pumped breast milk exposes newborns to more disease-causing bacteria than milk directly from the breast. The discovery suggests breastfeeding practices could shift the makeup of microorganisms in breast milk and infants’ digestive systems. “We were surprised that the method of feeding was the most consistent factor associate...

Children with ASD more likely to face maltreatment, study finds

A recent study by Vanderbilt researchers of 11 counties in Middle Tennessee revealed that children with autism spectrum disorder were nearly 2.5 times more likely than children without ASD to be reported to the Child Abuse Hotline by the age of 8.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks